Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: A case report and review of the hypothetical association between TNF-α blockers and cancer

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 195-199

  Kouklakis, George ^a   Efremidou, Eleni I ^a   Pitiakoudis, Michael ^a   Liratzopoulos, Nikolaos ^a   Polychronidis, Alexandros Ch ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Adalimumab; Causal relationship; Melanocytic proliferation; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; BUDENOFALK; BUDESONIDE;

ADULT; ADVERSE OUTCOME; ARTICLE; CASE REPORT; CLINICAL EVALUATION; COLONOSCOPY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE ANASTOMOSIS; INTESTINE OBSTRUCTION; LYMPH NODE BIOPSY; MELANOMA; OUTCOME ASSESSMENT; RELAPSE; SKIN BIOPSY; SKIN DEFECT; TREATMENT DURATION; WHOLE BODY CT;

ADALIMUMAB; CAUSAL RELATIONSHIP; MELANOCYTIC PROLIFERATION; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; CROHN DISEASE; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875655178     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S41889     Document Type: Article

References (33)

1. Katoulis AC, Kanelleas A, Zambacos G, Panayiotides I, Stavrianeas NG. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology. 2010;221(1):9-12.
2. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, etal. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56(Suppl 5):S65-S67.
3. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6): 1001-1017.
4. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(Suppl 2):ii30-ii36.
5. Mahmoud F, Abdul H, al Saleh Q, etal. Elevated B-lymphocyte levels in lesional tissue of non-arthritic psoriasis. J Dermatol. 1999;26(7): 428-433.
6. Müller KM, Röcken M, Joel D, Bonnefoy JY, Saurat JH, Hauser C. Mononuclear cell-bound CD23 is elevated in both atopic dermatitis and psoriasis. J Dermatol Sci. 1991;2(2):125-133.
7. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporine, and biologics: facts and controversies. Clin Dermatol. 2010;28(1):88-92.
8. Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2005;5(11):1491-1504.
9. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62(8):2517-2524.
10. Ehlers S, Hölscher C, Scheu S, etal. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol. 2003;170(10):5210-5218.
11. Wallis RS, Broder MS, Wong JY, Hanson ME, Beehouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-1265.
12. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285.
13. Stone JH, Holbrook JT, Marriott MA, etal; Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006;54(5):1608-1618.
14. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46(12):3151-3158.
15. Askling J, Fored CM, Baecklund E, etal. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists. Ann Rheum Dis. 2005;64(10): 1414-1420.
16. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32(11): 2130-2135.
17. Fryrear RS 2nd, Wiggins AK, Sangueza O, Yosipovitch G. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol. 2004;51(6):1026.
18. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-1691.
19. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45(6):953-956.
20. Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol. 2004;50(Suppl 5):S75-S77.
21. Askling J, Fored CM, Brandt L, etal. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis. 2005;64(10):1421-1426.
22. Ly L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol. 2007; 157(5):1076-1078.
23. Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol. 2007;82(11):1022-1024.
24. Hurley MY, George MN, Leonardi CL, Frater JL. A transient benign lymph node-based proliferation of T-cells stimulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists. Diagn Pathol. 2008;3:13-18.
25. Tyring S, Gordon KB, Poulin Y, etal. Long-term safety and efficacy of 50mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719-726.
26. Girard C, Guillot B, Bessis D. Gastric MALT lymphoma in a patient receiving infliximab for psoriasis. Br J Dermatol. 2008;159(2): 497-498.
27. Kouklakis G, Efremidou EI, Zezos P, etal. Adalimumab: an effective and promising treatment for patients with fistulizing Crohn's disease: a case series. J Med Case Rep. 2011;5:109.
28. Penn I. Malignant melanoma in organ allograft recipients. Transplantation. 1996;61(2):274-278.
29. Gordon KB, Langley RG, Leonardi C, etal. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598-606.
30. Kowalzick L, Eickenscheidt L, Komar M, Schaarschmidt E. Long term treatment of psoriasis with TNF-alpha antagonists: occurrence of malignant melanoma. Hautarzt. 2009;60(8):655-657. German [with English abstract].
31. Khan I, Rahman L, McKenna DB. Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol. 2009;34(4): 524-526.
32. Seminerio JL, Loftus EV Jr, Colombel JF, Thapa P, Sandborn WJ. Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci. Epub September 29, 2012.
33. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. Epub July 6, 2012.